



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# The Uptake of Integrated Perinatal Prevention of Mother-to-Child HIV Transmission Programs in Low- and Middle-Income Countries: A Systematic Review

### Citation for published version:

Car, LT, Brusamento, S, Elmoniry, H, van Velthoven, MHMMT, Pape, UJ, Welch, V, Tugwell, P, Majeed, A, Rudan, I, Car, J & Atun, R 2013, 'The Uptake of Integrated Perinatal Prevention of Mother-to-Child HIV Transmission Programs in Low- and Middle-Income Countries: A Systematic Review', *PLoS ONE*, vol. 8, no. 3, ARTN e56550. <https://doi.org/10.1371/journal.pone.0056550>

### Digital Object Identifier (DOI):

[10.1371/journal.pone.0056550](https://doi.org/10.1371/journal.pone.0056550)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Publisher's PDF, also known as Version of record

### Published In:

PLoS ONE

### Publisher Rights Statement:

Copyright: © 2013 Tudor Car et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# The Uptake of Integrated Perinatal Prevention of Mother-to-Child HIV Transmission Programs in Low- and Middle-Income Countries: A Systematic Review

Lorraine Tudor Car<sup>1</sup>, Serena Brusamento<sup>2</sup>, Hoda Elmoniry<sup>2</sup>, Michelle H. M. T. van Velthoven<sup>2</sup>, Utz J. Pape<sup>1</sup>, Vivian Welch<sup>3</sup>, Peter Tugwell<sup>3,4</sup>, Azeem Majeed<sup>1</sup>, Igor Rudan<sup>5</sup>, Josip Car<sup>2\*</sup>, Rifat Atun<sup>6</sup>

**1** Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom, **2** Global eHealth Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom, **3** Centre for Global Health, University of Ottawa, Ottawa, Canada, **4** Department of Medicine, University of Ottawa, Ottawa, Canada, **5** Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, United Kingdom, **6** Imperial College Business School, Imperial College London, London, United Kingdom

## Abstract

**Background:** The objective of this review was to assess the uptake of WHO recommended integrated perinatal prevention of mother-to-child transmission (PMTCT) of HIV interventions in low- and middle-income countries.

**Methods and Findings:** We searched 21 databases for observational studies presenting uptake of integrated PMTCT programs in low- and middle-income countries. Forty-one studies on programs implemented between 1997 and 2006, met inclusion criteria. The proportion of women attending antenatal care who were counseled and who were tested was high; 96% (range 30–100%) and 81% (range 26–100%), respectively. However, the overall median proportion of HIV positive women provided with antiretroviral prophylaxis in antenatal care and attending labor ward was 55% (range 22–99%) and 60% (range 19–100%), respectively. The proportion of women with unknown HIV status, tested for HIV at labor ward was 70%. Overall, 79% (range 44–100%) of infants were tested for HIV and 11% (range 3–18%) of them were HIV positive. We designed two PMTCT cascades using studies with outcomes for all perinatal PMTCT interventions which showed that an estimated 22% of all HIV positive women attending antenatal care and 11% of all HIV positive women delivering at labor ward were not notified about their HIV status and did not participate in PMTCT program. Only 17% of HIV positive antenatal care attendees and their infants are known to have taken antiretroviral prophylaxis.

**Conclusion:** The existing evidence provides information only about the initial PMTCT programs which were based on the old WHO PMTCT guidelines. The uptake of counseling and HIV testing among pregnant women attending antenatal care was high, but their retention in PMTCT programs was low. The majority of women in the included studies did not receive ARV prophylaxis in antenatal care; nor did they attend labor ward. More studies evaluating the uptake in current PMTCT programs are urgently needed.

**Citation:** Tudor Car L, Brusamento S, Elmoniry H, van Velthoven MHMT, Pape UJ, et al. (2013) The Uptake of Integrated Perinatal Prevention of Mother-to-Child HIV Transmission Programs in Low- and Middle-Income Countries: A Systematic Review. PLoS ONE 8(3): e56550. doi:10.1371/journal.pone.0056550

**Editor:** Marie-Louise Newell, Africa Centre for Health and Population Studies - University of KwaZulu-Natal, South Africa

**Received:** April 16, 2012; **Accepted:** January 14, 2013; **Published:** March 6, 2013

**Copyright:** © 2013 Tudor Car et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The Department of Primary Care & Public Health at Imperial College London. The Department of Primary Care & Public Health at Imperial College is grateful for support from the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research & Care Scheme, the NIHR Biomedical Research Centre scheme, and the Imperial Centre for Patient Safety and Service Quality. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: josip.car@imperial.ac.uk

## Introduction

In 2010, an estimated 16.8 million women and 3.4 million children were HIV positive [1]. Each day an estimated 1000 children under the age of 16 acquire HIV infection [1], over 90% of them due to mother-to-child transmission (MTCT) of HIV [1]. Transmission of HIV from mother to child can be reduced from 15–40% to 1% by effective prevention of mother to child transmission (PMTCT) of HIV programs [1].

When PMTCT programs were initially introduced in low- and middle-income countries, they were stand-alone programs, with gradual integration into maternal and newborn healthcare services [2,3] as one of the key strategies to improve coverage, achieve

universal access to PMTCT programs [4–8], and improve the quality of care delivered through better and synergistic use of scarce human and financial resources [7]. Implementing PMTCT programs integrated to routine healthcare services might help to reduce the stigma often experienced by HIV infected people [9,10]. However, many women in low- and middle-income countries do not attend maternal and child healthcare services [11]. Integrated or not, PMTCT services experience loss-to follow-up at each step of the program delivery: from the first contact, through counseling, HIV testing, collecting results, receiving antiretroviral therapy (ART) or prophylaxis, safe delivery practices, infant feeding recommendations up to postnatal follow-up; thereby reducing program effectiveness.

The uptake of PMTCT program is also influenced by the type of interventions implemented. The World Health Organization (WHO) has recommended the use of opt-out (i.e. offering testing routinely to all women entering care with an option to “opt-out” of testing), rapid HIV testing with return of results on the same day [12], and the use of virological tests in infants [13]. Virological test can be used earlier than an antibody test to identify HIV infections in infants since maternal HIV antibodies transferred passively during pregnancy can persist for as long as 18 months in children born to HIV-infected mothers and the interpretation of positive HIV antibody test results is more difficult in children below this age [14,15]. The aim of the WHO recommended HIV testing methods is to increase the number of women and children tested for HIV and knowing their serostatus as well as to improve access to HIV treatment.

In 2001, at the United Nations General Assembly Special Session (UNGASS), a goal was set to reduce the proportion of HIV infected infants by 50% by the year 2010 [16]. In order to achieve this target, an estimated 80% of pregnant women and their infants would need to have access to essential prevention, treatment and care [17]. Despite substantial international efforts, the progress on 4<sup>th</sup> and 5<sup>th</sup> Millennium Development Goals has been lagging behind the target [18,19].

Low coverage of PMTCT programs prompted the UN Secretary General and key UN agencies to call for increased domestic and international financing to address health of women and children to reach the 4<sup>th</sup> and 5<sup>th</sup> Millennium Development Goals and to expand the PMTCT coverage [20]. Furthermore, the UN Secretary General, G8 countries, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, in collaboration with its key partners the Joint United Nations Program on HIV/AIDS (UNAIDS), WHO, the United Nations Children’s Fund (UNICEF), the United Nations Population Fund (UNFPA) and the Children’s Investment Fund Foundation (CIFF) have committed to further develop and improve the quality and effectiveness of PMTCT services in low- and middle-income countries [20,21]. Integration of PMTCT with other healthcare services is a crucial component of this initiative [4,7,8,13,22].

Given the unacceptably large number of children affected by HIV at birth [1], poor PMTCT coverage [11], the potential impact of successful PMTCT programs and the international commitment to the improvement of these services, it is important to assess the effectiveness of integration of PMTCT services with other health services, such as maternal, newborn, and child health services. While several literature overviews explore integration of individual PMTCT interventions, the evidence on the uptake of these programs has not been systematically assessed [23–26]. The objective of this systematic review is to assess the uptake of integrated PMTCT programs in low- and middle-income countries.

## Methods

### Definition

This review focuses on the integration of the third prong of PMTCT interventions (Text S1), i.e. perinatal PMTCT interventions, which consist of HIV testing and counseling, provision of ART or antiretroviral (ARV) prophylaxis to women, safe delivery practices, infant feeding counseling, provision of ARV prophylaxis and HIV testing to the infant [27,28]. The PMTCT guidelines have changed several times since the beginning of PMTCT programs. This systematic review aims to present the overall uptake of PMTCT interventions and includes studies that

implemented or followed different versions of guidelines over the study time period.

We considered eligible studies on integration of PMTCT with antenatal care, labor ward care, postnatal/follow-up care, child healthcare services (e.g. immunization), nutrition services, voluntary counseling and testing (VCT) centers, HIV clinics, sexually transmitted infection (STI) clinics, reproductive health services and out-patient clinics. Given that PMTCT interventions in many settings are integrated with maternal and child health services, we developed a framework describing the integration of PMTCT program with antenatal care, labor ward and postnatal care (Table S1). There is no internationally agreed definition of integrated care [29–32]. We defined the integration of PMTCT interventions as joining of service delivery of PMTCT programs with other health care services, either at a single point of access (unified, full) or through referrals [33].

### Inclusion and exclusion criteria

We included observational studies performed in low- and middle-income countries as defined by the World Bank [34]. Studies had to focus on pregnant women, women in labor or in postpartum and infants with unknown HIV serostatus at enrolment in an integrated PMTCT program.


The primary outcome was the uptake of PMTCT programs, i.e. the proportion of women and children receiving individual PMTCT interventions (Text S2). In addition, we collected other relevant outcomes such as the proportion of HIV negative infants born to HIV positive women, costs, the impact on human resources, the quality of care, stigma, inequalities in access, barriers to implementation and sustainability of integrated programs and the impact on attendance (Text S2). We also included information about the follow-up i.e. provision of ART and co-trimoxazole to HIV positive women and HIV positive infants after the delivery. Exclusion criteria are listed in Text S3.

### Search strategy

We performed a comprehensive search to identify all relevant research regardless of the publication status, in any language with an English abstract. The search was conducted from 1990 (time of the first implementation of PMTCT programs) to August 2010. We used a highly sensitive search strategy developed in collaboration with the Cochrane HIV/AIDS Review Group. The search strategy did not entail search terms related to integrated care because in some studies “integration” could have been omitted or be apparent only from the description of service. We examined description of service delivery in each study to decide if it fits our definition of healthcare service integration.

### Electronic searches

We searched the following electronic databases: MEDLINE, EMBASE, the Cochrane Library, WHO The Global Health Library, Global Health CAB abstracts, CINAHL, POPLINE, PsychINFO, Sociological Abstracts, ERIC, the NLM Gateway system, and the Controlled-trials register and the WHO International Clinical Trials Registry for ongoing trials on PMTCT. We also searched several grey literature sources: New York Academy of Medicine Grey Literature Collection, Google Scholar, Open SIGLE, British Library Catalogue, AEGIS and ProQuest Dissertation & Theses Database (Text S4). We contacted authors of conference proceedings for additional information.



**Figure 1. PRISMA Flow diagram.**  
doi:10.1371/journal.pone.0056550.g001

### Screening process and data extraction

Two review authors independently performed selection of studies and data extraction. Disagreements between authors were resolved by discussion, consensus and consultation with a third review author. We screened titles and abstracts and then full-texts for eligibility. Data from the included studies were extracted using a standardized data extraction sheet (Table S2).

### Data analysis

We analyzed the data presented in the studies and performed narrative synthesis. The included studies used different denominators to present the proportion of participants receiving perinatal PMTCT intervention which we recalculated and standardized (Text S5). We separately analyzed the studies which described the implementation of the PMTCT program in antenatal care and at labor ward level. For pregnant women enrolled at antenatal care we separately described the proportion of women receiving ARV

prophylaxis in antenatal care, the proportion receiving it at labor ward and the total proportion of women who received ARV prophylaxis at delivery (consisting of women who received ARV prophylaxis in antenatal care and self-reported that they have taken it during home delivery and women who took the prophylaxis at the labor ward).

Statistical analysis was carried out based on non-parametric tests since distributional assumptions were not satisfied. The Wilcoxon rank sum test was applied to perform all comparisons between two groups [35]. Differences in outcome for the three World Bank income groups, namely low-, lower-middle, upper-middle income countries were tested by an extended rank sum test developed by Cuzick [36]. We used a rank sum trend test, which is a natural extension of the Wilcoxon rank sum test for two groups, as a non-parametric statistic to consider the trend between more than two groups.

We designed two cascades with the data from the studies reporting on the uptake of each step of perinatal PMTCT programs [37,38]. The first cascade presents integration of PMTCT interventions in antenatal care and the second cascade illustrates the integration of PMTCT interventions at labor ward. Both cascades pool the studies weighted by the number of participating women. The fractions are relative to the number of women attending antenatal care in the first cascade and the number of women eligible for HIV test at labor ward in the second cascade. The first cascade assumes that the HIV prevalence is equal among women who accepted and those who declined testing. This assumption is probably conservative as women might decline testing since they feel likely to be positive. Hence, the real number of HIV positive among women who declined testing is probably higher than our estimate. However, we imply that selection into testing did not result in a higher number of positive HIV tests, which could arguably be the case if once tested women refrain from a repeated test as they correctly assume that they are still negative. We made the same assumption for the second cascade to estimate the proportion of unidentified HIV positive women.

## Results

### Study characteristics

Our search strategy identified 28 654 references (Figure 1 and Table S3). One hundred and twenty one articles and 218 relevant conference abstracts passed the first screening of titles and abstracts. After full text assessment, we excluded 86 articles (Table S4). We contacted authors of relevant conference abstracts for further information resulting in one included abstract. Forty one studies met inclusion criteria (Table 1 and Figure 1). We found two second reports: a French version of an English article [39], and a brief additional description of a program already reported in one of the included studies [40]. Except one article in Spanish [41], all the included studies were in English.

Twenty five studies were conducted in Sub-Saharan Africa [42–66], six in Latin America-Caribbean [41,67–71], nine in Asia [72–80], and one in Ukraine [81]. Of the 41 included studies, 17 described PMTCT programs in low-income [46–50,52–55,57–59,61–63,67,80], 15 in lower-middle income [41,43–45,56,64,65,70,72,74,76–79,81], and nine in upper-middle income countries [42,51,60,66,68,69,71,73,75]. The presented PMTCT programs were implemented at different time periods between years 1997 and 2006 (Figure S1). Twelve programs occurred in countries where HIV prevalence was between 5% and 10% (Table S5). The general HIV prevalence in 18 studies was less than 5% and more than 10% in 11 programs, all of which

were implemented in Africa (Table S5). PMTCT interventions were mostly integrated with maternal and child health services, i.e. antenatal care, labor wards, and postnatal care. The infant follow up was integrated with immunization centers in two studies [61,63]. In one study the PMTCT was integrated with HIV/AIDS treatment centers [81]. Participants, staff, setting and interventions from integrated PMTCT programs are presented in Texts S6 and S7 and Table S6.

## Outcomes

**Primary outcomes.** In 34 studies women were enrolled in integrated PMTCT program in antenatal care. In most of these studies ( $n = 28$ ), women were followed from antenatal care until delivery [41–51,53–59,61–69,71,74–77,79,81]. In seven studies women were enrolled into the integrated PMTCT programs at labor ward [60,70–73,75,78]. In two studies women entered the integrated program both at antenatal and labor ward care [80,82].

**Integration of perinatal PMTCT program with antenatal care.** The main outcomes from the 34 studies which reported on the PMTCT program integrated in antenatal care are displayed in Table 2. We performed subgroup analyses to analyze the impact of different strategies on the coverage within studies focusing on antenatal care integration (Text S8).

**Integration of perinatal PMTCT program with labor ward care.** The primary outcomes reported in the studies which focused on integration of PMTCT with labor ward are shown in Table 3 [52,60,70–73,75,78,80]. In those studies pregnant women were eligible for HIV testing if they had unknown or undocumented HIV status at their entrance in labor ward. Additionally, in two studies from Russia women who had a previous negative HIV test performed before 34 weeks of pregnancy were also considered eligible for repeat testing [75].

**Integration of perinatal PMTCT program with labor ward care: safe delivery.** Only nine studies had quantitative data on safe delivery practices [41,45,47,56,58,66,68,69,71]. In two studies performed in low-income countries caesarean section was not available [47,58]. In the other seven studies the proportion of HIV positive pregnant women who underwent elective caesarean section varied from 17% to 63% (median 28%) [41,45,56,68,69,71]. Five of these studies were performed in upper-middle income countries [41,66,68,69,71,83] and two in lower-middle income countries [45,56].

Fifteen studies provided extractable data on the proportion of women who entered into the PMTCT program in antenatal care and delivered at hospital [41,45,47,54,56–59,61,64,66,68,69,74,77]. The median proportion was 60% (range 19–100%), and it significantly varied across the World Bank income groups: 44% (range 19–60%) in studies performed in low-income [47,54,58,59,61], 86% (range 43–100%) in lower-middle income [45,56,64,74,77], and 100% (range 89–100%) among the upper-middle income countries ( $P < 0.0001$ ) [41,66,69].

**Integration of perinatal PMTCT program with postnatal/follow-up care.** The outcomes from the studies reporting coverage of infant ARV prophylaxis and HIV testing are presented in Table 4. Within the 13 studies with data on infant testing [41,47,51,56,57,64,66,68,69,71,75,78,79], six used a rapid test at 12, 15 and 18 months [47,51,64,68,69,71], while in seven a PCR test or viral load was used within the first six months of life [41,56,57,66,75,78,79]. The proportion of children tested at least once was not significantly different between those two groups of studies, 82% (range 48–100%) versus 76% (range 44–100%),  $P = 0.548$ .

A study on integrated PMTCT program in Vietnam is described separately due to particularities of the program. In this

**Table 1.** Characteristics of included observational studies.

| Author/Year/<br>Location/Study<br>period                    | Participants/<br>Sample size<br>(n)/Setting              | Settings  | Program Integration  | Opt in vs opt out/Type<br>of HIV test/ARV regimen<br>(Woman/Infant)  | Primary outcomes reported   |
|---|--|---|--|--|---|
| Abdullah et al,[42]<br>2001 RSA Jan-99–<br>Dec-00           | Women ANC/<br>Attendees: 14<br>139/ Urban                | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at primary<br>healthcare level/<br>LW at hospital level | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis,<br>Feeding counseling/ PNC:<br>Testing infants                              | Opt-in/ Women: ELISA test<br>later substitute with rapid<br>test; Infants: antibody test/<br>Women: AZT; Infants: -  | ANC: Percentage of women who received<br>information on PMTCT; Percentage of<br>women tested; Percentage of women who<br>received their test result; Percentage of HIV<br>positive women who received their test<br>result; Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis  |
| Behets et al, [50]<br>2009 DRC<br>Jun-03 –Jul-05            | Women ANC/<br>Attendees: 45<br>262/ Urban                | PMTCT Integration:<br>ANC, LW/ LW at<br>hospital level  | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Women prophylaxis,<br>Infant prophylaxis  | Opt-in/ Women:<br>unspecified; Infants: - /<br>Women: sd-NVP;<br>Infants: sd-NVP   | ANC: Percentage of women who received<br>their test result; Percentage of HIV positive<br>women who received their test result;<br>Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis   |
| Bharucha et al,[72]<br>2005 India Apr-01–<br>Mar-02         | Women LW/<br>Eligible: 1308/<br>Urban                    | PMTCT integration:<br>LW/ LW at hospital<br>level   | LW: Testing women,<br>Women prophylaxis  | Opt-in/ Women: rapid<br>test (+ confirmatory test);<br>Infants: - / Women:<br>sd-NVP or AZT during<br>delivery; Infants: -   | LW: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis   |
| Deschamps<br>et al,[67] 2009 Haiti<br>Jun-05– Jun-05        | Women ANC/<br>HIV tested:<br>5270/ Urban                 | PMTCT integration:<br>ANC, PNC  | ANC: Testing women,<br>Women ART, Women<br>prophylaxis/ LW: Women<br>prophylaxis/ PNC: Feeding<br>counseling, Testing<br>infants, infant prophylaxis                   | Opt-in/ Women: rapid<br>test; Infants: PCR within<br>the first 6 months of life/<br>Women: sd-NVP or AZT<br>orally during delivery;<br>Infants : AZT for 1 week  | ANC: Percentage of women tested,<br>Percentage of women receiving ARV<br>prophylaxis  |
| Doherty et al,[67]<br>2005 RSA<br>Jan-02 – Dec-02           | Women ANC/<br>Attendees: 84<br>406/ Urban and<br>rural   | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level        | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Infant prophylaxis/ PNC:<br>Testing infants  | -/ Women: rapid test;<br>Infants: antibody test/<br>Women: sd-NVP; Infants:<br>sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of<br>women receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative  |
| Ekouevi et al,[43]<br>2004 Côte d'Ivoire<br>May- 00- Oct-02 | Women ANC/<br>Counseled on<br>PMTCT: 14 067/<br>Rural    | PMTCT integration:<br>ANC, LW/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level                       | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis,<br>Infant prophylaxis   | Opt-in/ Women: rapid<br>test (+ confirmatory test);<br>Infants: -/ Women AZT<br>from 36weeks plus sd-NVP;<br>Infants: -  | ANC: Percentage of women who received<br>their test result, Percentage of HIV positive<br>women who received their test result,<br>Percentage of women receiving ARV<br>prophylaxis   |
| Garcia et al,[41]<br>2005 Colombia<br>Mar-03- Mar-05        | Women ANC/<br>HIV tested:<br>200 853/ Urban<br>and Rural | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level        | ANC: Testing women/ LW:<br>Women prophylaxis, Safe<br>delivery, Infant<br>prophylaxis/ PNC: Testing<br>infants   | Opt-in/ Women: ELISA and<br>Western blot; Infants: Viral<br>load within first 6 months<br>of life/ Women: AZT-3TC/<br>AZT-3TC-NVP during<br>pregnancy, AZT / sd-NVP/<br>AZT+sd-NVP at delivery;<br>Infants: AZT+3TC for<br>6 weeks | ANC: Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis, Percentage of<br>women having elective caesarean section/<br>PNC: Percentage of infants receiving ARVs<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative   |
| Geddes et al,[66]<br>2008 RSA Mar-04 –<br>Aug-05            | Women ANC/<br>Attendees: 2624/<br>Urban                  | PMTCT integration:<br>across ANC,<br>LW, PNC/ ANC<br>and LW at hospital<br>level                                    | ANC: Testing women,<br>Feeding counseling,<br>Women ART, Women<br>prophylaxis/ LW: Women<br>prophylaxis, Safe delivery,<br>Infant prophylaxis/ PNC:<br>Testing infants | Opt-in/ Women: rapid test;<br>Infants: PCR within the<br>first 6 months of life/<br>Women: AZT during<br>pregnancy, sd-NVP/<br>AZT+sd-NVP at delivery<br>or HAART for life; Infants:<br>sd-NVP/ AZT+sd-NVP                         | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of<br>women receiving ARV prophylaxis/ LW:<br>Percentage of women having elective<br>caesarean section/ PNC: Percentage of<br>infants receiving ARVs prophylaxis,<br>Percentage of infants tested, Percentage of<br>exposed infants who resulted HIV negative |
| Hillis et al,[73]<br>2007 Russia<br>Apr-04 – Oct-04         | Women LW/<br>Eligible for HIV<br>test: 709/ Urban        | PMTCT<br>integration: LW  | LW: Testing women,<br>Women prophylaxis,<br>Infant prophylaxis   | -/ Women: EIA and<br>Western blot; Infants: - /<br>Women: sd-NVP; Infants:<br>sd-NVP   | LW: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis   |

Table 1. Cont.

| Author/Year/<br>Location/Study<br>period                         | Participants/<br>Sample size<br>(n)/Setting  | Settings   | Program Integration   | Opt in vs opt out/Type<br>of HIV test/ARV regimen<br>(Woman/Infant)   | Primary outcomes reported   |
|--|--|--|---|---|---|
| Homsy et al,[52]<br>2006 Uganda<br>Dec-04 – Sept-05              | Women ANC/<br>Attendees:<br>3765/ Rural  | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level                                | ANC: Testing women,<br>Women ART (referral),<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Testing women, Feeding<br>counseling, Women<br>prophylaxis, Infant<br>prophylaxis/ PNC:<br>Testing infants | Opt-out/ Women:<br>rapid test; Infants: -/<br>Women: sd-NVP; Infants:<br>sd-NVP   | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ LW: Percentage<br>of women who received information on<br>PMTCT, Percentage of women tested,<br>Percentage of women receiving ARV<br>prophylaxis/ PNC: Percentage of Infants<br>receiving ARV prophylaxis   |
| Kanshana et al,[74]<br>2000 Thailand<br>Jul-98 – Jun-99          | Women ANC/<br>Attendees: 60<br>403/ Urban<br>and Rural   | PMTCT integration:<br>across ANC, LW,<br>PNC/ LW at<br>hospital level  | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis/ PNC:<br>Testing infants  | Opt-in/ Women: rapid<br>test (+ confirmatory test);<br>Infants: antibody test/<br>Women: AZT from<br>36 weeks and delivery;<br>Infants: -         | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested/ LW: Percentage of women<br>receiving ARV prophylaxis  |
| Karcher et al,[53]<br>2006 Tanzania<br>Uganda Mar-02 –<br>Dec-04 | Women ANC/<br>Tanzania<br>Attendees: 22<br>664/ Uganda<br>Attendees: 29<br>520/ Urban<br>and rural | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Women prophylaxis, Infant<br>prophylaxis/ PNC: Feeding<br>counseling   | -/ Women: rapid test;<br>Infants: - / Women:<br>sd-NVP; Infants: sd-NVP   | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ LW: Percentage<br>of women receiving ARV prophylaxis/ PNC:<br>Percentage of Infants receiving ARVs<br>prophylaxis   |
| Kasenga et al,[54]<br>2007 Malawi<br>Jan-05 – Jun-05             | Women ANC/<br>Attendees:<br>719/ Rural   | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level                                | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Infant prophylaxis/ PNC:<br>Feeding counseling,<br>Testing infants   | Opt-out/ Women:<br>unspecified; Infants:<br>antibody test/ Women:<br>sd-NVP; Infants: sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ LW: Percentage<br>of women receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis  |
| Kirere et al,[55]<br>2008 DRC<br>Dec-02 – Dec-04                 | Women ANC/<br>HIV tested:<br>5016/ Rural   | PMTCT integration:<br>ANC, LW/ ANC<br>and LW at<br>hospital level  | ANC: Testing women/ LW:<br>Women prophylaxis, Infant<br>prophylaxis   | -/ Women: rapid test;<br>Infants: - / Women:<br>sd-NVP; Infants: sd-NVP   | LW: Percentage of women receiving ARV<br>prophylaxis/ PNC: Percentage of infants<br>receiving ARV prophylaxis   |
| Kissin et al,[75]<br>2008 Russia<br>Apr-04 – Apr-05              | Women LW/<br>Eligible for HIV<br>test: 4117/<br>Urban  | PMTCT integration:<br>across ANC, LW,<br>PNC/ LW at<br>hospital level  | ANC: Testing women/ LW:<br>Testing women, Feeding<br>counseling, Women<br>prophylaxis, Infant<br>prophylaxis, Women ART<br>(referral), Testing infants/<br>PNC: Testing infants                             | Opt-out/ Women: rapid<br>test (+ confirmatory test);<br>Infants: PCR within the<br>first six months of life/<br>Women: sd-NVP; Infants:<br>sd-NVP | LW: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative  |
| Kuam et al,[56]<br>2006 Cameroon<br>Jan-03 – Dec-04              | Women ANC/<br>Attendees: 432/<br>Urban   | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level                                | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Safe delivery, Feeding<br>counseling, Women<br>prophylaxis, Infant<br>prophylaxis/ PNC:<br>Feeding counseling,<br>Testing infants                          | -/Women: rapid test (+<br>confirmatory test); Infants:<br>Viral load/ Women: sd-NVP;<br>Infants: sd-NVP   | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>having elective caesarean section/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative |
| Le et al,[76] 2008<br>Vietnam Jan-00 –<br>Oct-02                 | Women ANC;<br>Women<br>LW/ Total<br>attendees: 215<br>683/ Urban                                   | PMTCT integration:<br>ANC, LW/ LW at<br>hospital level   | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Testing women, Feeding<br>counseling, Women<br>prophylaxis, Infant<br>prophylaxis  | Mandatory/ Women:<br>EIA (+ confirmatory test);<br>Infants: - / Women:<br>sd-NVP or AZT at<br>delivery; Infants:<br>sd-NVP/AZT +sd-NVP            | LW: Percentage of women receiving ARV<br>prophylaxis/ PNC: Percentage of infants<br>receiving ARVs prophylaxis  |
| Magoni et al,[57]<br>2007 Uganda<br>Jan-00 – Dec-04              | Women ANC/<br>Attendees: 26<br>556/ Urban  | PMTCT integration:<br>ANC, PNC/ ANC at<br>hospital level   | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis,<br>Testing infants/ PNC:<br>Testing infants  | -/Women: rapid test;<br>Infants: antibody test/<br>Women: AZT from<br>36 weeks, AZT or<br>sd-NVP at delivery;<br>Infants: -                       | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants tested, Percentage of<br>exposed infants who resulted HIV negative  |



Table 1. Cont.

| Author/Year/<br>Location/Study<br>period                      | Participants/<br>Sample size<br>(n)/Setting        | Settings  | Program Integration  | Opt in vs opt out/Type<br>of HIV test/ARV regimen<br>(Woman/Infant)   | Primary outcomes reported   |
|---|--|---|--|---|---|
| Malyuta et al.[81]<br>2006 Ukraine<br>Jan-02 – Dec-02         | Women ANC/<br>Attendees: 408<br>354/ Urban         | PMTCT integration:<br>across ANC<br>(HIV Clinic), LW,<br>PNC/ ANC at primary<br>healthcare level/<br>LW at hospital level | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Testing women, Women<br>prophylaxis, Infant<br>prophylaxis/ PNC: Testing<br>infants/ AIDS center:<br>Feeding counseling,<br>Testing infants         | Opt-in/Women: ELISA in<br>ANC, rapid test at LW;<br>Infants: antibody test/<br>Women: AZT from<br>36 weeks, AZT or sd-NVP<br>at delivery; Infants:<br>sd-NVP  | ANC: Percentage of women tested,<br>Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis  |
| Manzi et al.[58]<br>2005 Malawi<br>Mar-02 – Sep-03            | Women ANC/<br>Attendees:<br>3136/-                 | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and LW<br>at hospital level   | ANC: Testing women,<br>Safe delivery, Feeding<br>counseling, Women<br>prophylaxis/ LW: Safe<br>delivery, Feeding<br>counseling, Women<br>prophylaxis, Infant<br>prophylaxis/ PNC:<br>Testing infants | Opt-out/ Women:<br>rapid test; Infants:<br>antibody test/ Women:<br>sd-NVP; Infants: sd-NVP   | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis         |
| Miranda et al.[68]<br>2005 Brazil<br>1997 – 2001              | Women ANC/<br>Attendees: 25<br>224/ Urban          | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level              | ANC: Testing women,<br>Women prophylaxis/ LW:<br>Testing women, Feeding<br>counseling, Women<br>prophylaxis, Infant<br>prophylaxis/ PNC:<br>Testing infants  | Opt-out/ Women:<br>ELISA (+ confirmatory<br>test); Infants: PCR within<br>the first six months of<br>life/ Women: AZT from<br>14 weeks and delivery;<br>Infants: AZT for 6 weeks  | ANC: Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis, Percentage of<br>women having elective caesarean section/<br>PNC: Percentage of infants receiving ARVs<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative   |
| Moth et al.[59]<br>2005 Kenya<br>Feb-03 – Mar-03              | Women ANC/<br>Attendees: 1268/<br>Urban            | PMTCT integration:<br>ANC, LW/ ANC<br>and LW at<br>hospital level   | ANC: Testing women/<br>LW: Women prophylaxis,<br>Infant prophylaxis  | -/ Women: unspecified;<br>Infants: - / Women:<br>sd-NVP; Infants: sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested/ LW: Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis   |
| Msellati et al.[44]<br>2001 Côte d'Ivoire<br>Oct-98 – Apr- 99 | Women ANC/<br>Attendees:<br>4309/ Urban            | PMTCT integration:<br>ANC, LW/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level                             | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis  | Opt-in/ Women: ELISA test;<br>Infants: - / Women:<br>AZT from 36 weeks and<br>delivery; Infants: -  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis  |
| Nagdeo et al.[77]<br>2007 India<br>Feb-03 – Jun-06            | Women ANC/<br>Attendees:<br>7897/ Rural            | PMTCT integration:<br>ANC, LW/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level                             | ANC: Testing women/ LW:<br>Women prophylaxis,<br>Infant prophylaxis  | -/ Women: unspecified;<br>Infants: - / Women:<br>sd-NVP; Infants: sd-NVP  | LW: Percentage of women receiving ARV<br>prophylaxis/ PNC: Percentage of infants<br>receiving ARV prophylaxis   |
| Onah et al.[45]<br>2008 Nigeria<br>Mar-05 – Sept-05           | Women ANC/<br>Attendees:<br>635/ Urban             | PMTCT integration:<br>ANC, LW/ ANC<br>and LW at<br>hospital level   | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis, Safe<br>delivery/ LW: Women<br>prophylaxis, Safe delivery,<br>Infant prophylaxis,<br>Feeding counseling                             | Opt-out/ Women: ELISA<br>and Western blot;<br>Infants: - / Women:<br>sd-NVP; Infants: sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result/ LW: Percentage of women receiving<br>ARV prophylaxis, Percentage of women<br>having elective caesarean section/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis |
| Pai et al.[78]<br>2008 India<br>Jan-06 – Sep-06               | Women LW/<br>Eligible for HIV<br>test: 1252/ Rural | PMTCT integration:<br>LW, PNC/ LW at<br>hospital level  | LW: Testing women,<br>Feeding counseling,<br>Women prophylaxis,<br>Safe delivery, Infant<br>prophylaxis/ PNC:<br>Testing infants,<br>Feeding counseling  | -/ Women: rapid test<br>(+confirmatory test);<br>Infants: PCR within the<br>first 6 months of life/<br>Women: AZT-3TC-sd-NVP<br>during delivery plus<br>AZT-3TC 1 week after<br>delivery; Infants:<br>sd-NVP + AZT for 1 week | LW: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative   |



Table 1. Cont.

| Author/Year/<br>Location/Study<br>period                    | Participants/<br>Sample size<br>(n)/Setting           | Settings   | Program Integration  | Opt in vs opt out/Type<br>of HIV test/ARV regimen<br>(Woman/Infant)  | Primary outcomes reported   |
|---|---|--|--|--|---|
| Parameshwari<br>et al,[79] 2009<br>India Oct-02 –<br>Dec-07 | Women ANC/<br>Attendees:<br>7866/ Rural               | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level                                | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis,<br>Infant prophylaxis,<br>PNC, Testing infants  | -/ Women: rapid<br>test (+ confirmatory<br>test); Infants: PCR within<br>the first 6 months of life/<br>Women: sd-NVP; Infants:<br>sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative   |
| Perez et al,[46,94]<br>2004 Zimbabwe<br>Aug-01- Feb-03      | Women ANC/<br>Attendees:<br>2470/ Rural               | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level                                | ANC: Testing women,<br>Feeding counseling/ LW:<br>Women prophylaxis,<br>Infant prophylaxis/ PNC:<br>Feeding counseling   | Opt-in/ Women: rapid test;<br>Infants: - /Women: sd-NVP;<br>Infants: sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis   |
| Rose et al,[60]<br>2005 RSA<br>Jan-03 – Dec-05              | Women LW/<br>Eligible for<br>HIV test:<br>7500/ Urban | PMTCT integration:<br>LW (postpartum)/ LW<br>at hospital level   | LW: Testing women,<br>Infant prophylaxis,<br>Feeding counseling  | -/ Women: rapid<br>test (+ confirmatory<br>test); Infants: - /<br>Women: - ; Infants:<br>sd-NVP  | LW: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested/ PNC: Percentage of infants<br>receiving ARVs prophylaxis   |
| Rutta et al,[47]<br>2008 Tanzania<br>Oct-02 – Sep-04        | Women ANC/<br>Attendees: 10<br>666/ Refugees<br>camp  | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level | ANC: Testing women,<br>Feeding counseling,<br>Safe delivery, Women<br>prophylaxis/ LW: Safe<br>delivery, Women<br>prophylaxis, Infant<br>prophylaxis/ PNC:<br>Testing infants                            | Opt- out/ Women:<br>rapid test (+ confirmatory<br>test); Infants: antibody<br>test/ Women: sd-NVP;<br>Infants: sd-NVP                      | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative |
| Saman et al,[80]<br>2002 Cambodia<br>July-00 – Jun-01       | Women ANC/<br>Attendees:<br>2079/ Urban               | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level                                | ANC: Testing women,<br>Feeding counseling/ LW:<br>Testing women, Women<br>prophylaxis, Infant<br>prophylaxis, Feeding<br>counseling/ PNC:<br>Testing infants   | -/ Women: rapid<br>test (+ confirmatory<br>test); Infants: PCR within<br>the first 6 months of life/<br>Women: sd-NVP; Infants:<br>sd-NVP  | ANC: Percentage of women who received<br>their test result/ LW: Percentage of women<br>who received information on PMTCT,<br>Percentage of women tested, Percentage<br>of women receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis  |
| Saraceni et al,[69]<br>2000 Brazil<br>Jun-97 – Jun-05       | Women ANC/<br>Attendees: 202<br>950-                  | PMTCT integration:<br>across ANC, LW,<br>PNC/ LW at<br>hospital level  | ANC: Testing women,<br>Feeding counseling,<br>Women ART (referral),<br>Women prophylaxis/ LW:<br>Women prophylaxis, Safe<br>delivery, Infant<br>prophylaxis/ PNC: Feeding<br>counseling, Testing infants | -/ Women: ELISA<br>substituted with rapid<br>test; Infants: antibody<br>test/ Women: AZT during<br>pregnancy and delivery;<br>Infants: AZT | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women<br>receiving ARV prophylaxis/ LW: Percentage<br>of women receiving ARV prophylaxis,<br>Percentage of women having elective<br>caesarean section/ PNC: Percentage of<br>infants tested, Percentage of exposed<br>infants who resulted HIV negative   |
| Schumacher<br>et al,[70] 2009<br>Guyana Jan-06 –<br>Mar-06  | Women LW/ HIV<br>status unknown:<br>360               | PMTCT integration:<br>LW/ LW at hospital<br>level  | LW: Testing women,<br>Women prophylaxis,<br>Infant prophylaxis   | -/ Women: unspecified;<br>Infants: - / Women:<br>sd-NVP, Infants: sd-NVP   | LW: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested/ PNC: Percentage of infants<br>receiving ARV prophylaxis  |
| Shetty et al,[62]<br>2005 Zimbabwe<br>July-99 - June-01     | Women ANC/<br>Attendees:<br>6051/ Urban               | PMTCT integration:<br>ANC/ ANC at<br>primary healthcare<br>level   | ANC: Testing women,<br>Women prophylaxis   | Opt-in/ Women: rapid<br>test (+ confirmatory test);<br>Infants: - / Women:<br>AZT from 36 weeks;<br>Infants: -                             | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis  |

Table 1. Cont.

| Author/Year/<br>Location/Study<br>period                | Participants/<br>Sample size<br>(n)/Setting                        | Settings  | Program Integration   | Opt in vs opt out/Type<br>of HIV test/ARV regimen<br>(Woman/Infant)   | Primary outcomes reported   |
|---|--|---|---|---|---|
| Shetty et al,[61]<br>2008 Zimbabwe<br>Oct-02 - Dec-04   | Women ANC/<br>Attendees: 19<br>279/ Urban                          | PMTCT integration:<br>across ANC, LW,<br>PNC (Immunization<br>clinic)/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis,<br>Infant prophylaxis/ PNC:<br>Testing infants   | Opt-in/ Women: rapid test;<br>Infants: antibody test/<br>Women: sd-NVP;<br>Infants: sd-NVP  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis/ PNC:<br>Percentage of infants receiving ARVs<br>prophylaxis |
| Stringer et al,[48]<br>2003 Zambia<br>Nov-01- Oct-02    | Women ANC/<br>Counseled on<br>PMTCT: 17 263/<br>Urban              | PMTCT integration:<br>across ANC, LW,<br>PNC/ LW at<br>hospital level   | ANC: Testing women,<br>Women prophylaxis,<br>Feeding counseling/ LW:<br>Women prophylaxis,<br>Infant prophylaxis/ PNC:<br>Testing infants   | Opt-in/ Women: rapid test;<br>Infants: antibody test/<br>Women: sd-NVP;<br>Infants: sd-NVP  | ANC: Percentage of women who received<br>their test result, Percentage of women<br>receiving ARV prophylaxis  |
| Temmerman et<br>al,[49] 2003 Kenya<br>Apr- 01 - Apr- 02 | Women ANC/<br>Attendees:<br>3660/ Urban                            | PMTCT integration:<br>ANC, LW/ ANC<br>and LW at hospital<br>level   | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis,<br>Infant prophylaxis/ LW:<br>Women prophylaxis,<br>Infant prophylaxis   | Opt-in/ Women: rapid test;<br>Infants: - / Women: sd-NVP;<br>Infants: sd-NVP, provided at<br>ANC to administer during<br>home delivery  | ANC: Percentage of women who received<br>information on PMTCT, Percentage of<br>women tested, Percentage of women who<br>received their test result, Percentage of HIV<br>positive women who received their test<br>result, Percentage of women receiving ARV<br>prophylaxis/ LW: Percentage of women<br>receiving ARV prophylaxis  |
| Torpey et al,[63]<br>2010 Zambia<br>Jul-05 – Sep-08     | Women ANC/<br>Counseled on<br>PMTCT:<br>34 780/ Urban<br>and Rural | PMTCT Integration:<br>across ANC, LW,<br>PNC (Immunization<br>clinic)/ANC at<br>primary healthcare<br>level/ LW at<br>hospital level  | ANC: Testing women,<br>Women prophylaxis  | Opt-out/ Women: rapid test<br>(+ confirmatory test); Infants:<br>their test result, Percentage of HIV positive<br>PCR within the first 6 months<br>of life/ Women: sd-NVP;<br>Infants: sd-NVP           | ANC: Percentage of women who received<br>their test result, Percentage of HIV positive<br>women who received their test result,<br>Percentage of women receiving ARV<br>prophylaxis   |
| Viani et al,[71]<br>2010 Mexico<br>Mar- 03 - Dec-05     | Women ANC/<br>17 at ANC and<br>45 at LW/<br>Urban                  | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC and<br>LW at hospital level   | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Testing women, Women<br>prophylaxis, Safe delivery,<br>Infant prophylaxis,<br>Feeding counseling/ PNC:<br>Testing infants | -/ Women: rapid test (+<br>confirmatory test); Infants:<br>PCR within the first six<br>months of life/ Women:<br>AZT-3TC-NFV during<br>pregnancy or AZT during<br>delivery; Infants: AZT for<br>6 weeks | ANC: Percentage of women receiving ARV<br>prophylaxis, Percentage of women having<br>elective caesarean section/ PNC:<br>Percentage of infants receiving ARV<br>prophylaxis, Percentage of infants tested,<br>Percentage of exposed infants who<br>resulted HIV negative  |
| Wanyu et al,[64]<br>2007 Cameroon<br>Jul-02 – Jun-05    | Women ANC/<br>Counseled on<br>PMTCT: 2331/<br>Rural                | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at hospital<br>level                          | ANC: Testing women,<br>Feeding counseling/ LW:<br>Women prophylaxis,<br>Infant prophylaxis/ PNC:<br>Testing infants   | Opt-in/ Women: rapid test;<br>Infants: antibody test/<br>Women: sd-NVP; Infants:<br>sd-NVP  | ANC: Percentage of women who received<br>their test result, Percentage of HIV positive<br>women who received their test result/ LW:<br>Percentage of women receiving ARV<br>prophylaxis/ PNC: Percentage of infants<br>receiving ARV prophylaxis, Percentage of<br>infants tested, Percentage of exposed<br>infants who resulted HIV negative   |
| Welty et al,[65]<br>2005 Cameroon<br>Feb-00 – Dec-04    | Women ANC;<br>Counseled on<br>PMTCT: 68 635/<br>Urban and rural    | PMTCT integration:<br>across ANC, LW,<br>PNC/ ANC at<br>primary healthcare<br>level/ LW at<br>hospital level                          | ANC: Testing women,<br>Feeding counseling,<br>Women prophylaxis/ LW:<br>Women prophylaxis,<br>Infant prophylaxis/<br>PNC:Testing infants  | -/ Women: rapid test;<br>Infants: PCR within<br>the first 6 months of<br>life/ Women: sd-NVP;<br>Infants: sd-NVP  | ANC: Percentage of women who received<br>their test result, Percentage of HIV positive<br>women who received their test result/ PNC:<br>Percentage of exposed infants who<br>resulted HIV negative  |

Abbreviations: ANC, antenatal care; ART, antiretroviral therapy; ARV, antiretroviral; AZT, zidovudine; DRC, Democratic Republic of Congo; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; HAART, highly active antiretroviral therapy; LW, labor ward; NVF, nelfinavir; PMTCT, prevention of mother to child transmission; PCR, polymerase chain reaction; PNC, postnatal care; RSA, Republic of South Africa; sd-NVP, single dose nevirapine; 3TC, lamivudine.  
doi:10.1371/journal.pone.0056550.t001

study, HIV testing in antenatal care and at labor ward was mandatory and women had to pay for it. Given that women had to wait for the results of the tests for at least one week, most of the women who were tested at labor ward and their infants did not receive ARV treatment. The authors stated that 28.3% of the HIV positive women and 4.1% of their infants received ARV

prophylaxis. The study did not report separate results for women tested in antenatal care and those tested at labor ward [76].

The proportion of women counseled on infant feeding was not explicitly stated in any of the included studies but most of them reported that women participating in PMTCT programs received infant feeding recommendation as a part of the counseling.

**Table 2.** Uptake of integrated PMTCT programs in which women were enrolled in antenatal care.

| World Bank Income Group  | Low Income               | Lower Middle Income      | Upper Middle Income      | ALL                      | P                  |
|--|--------------------------|--------------------------|--------------------------|--------------------------|--------------------|
|  | Median (range) n studies | Median (range) n studies | Median (range) n studies | Median (range) n studies |                    |
| <b>Percentage of ANC attendees who received information on PMTCT</b>   | 92% (30–98%) 12          | 100% (87–100%) 5         | 100% (100–100%) 4        | 96% (30–100%) 21         | 0.001 <sup>a</sup> |
| <b>Percentage of ANC attendees HIV tested</b>  | 69% (26–95%) 12          | 89% (80–100%) 6          | 81% (56–100%) 4          | 81% (26–100%) 22         | 0.048 <sup>b</sup> |
| <b>Percentage of HIV tested ANC attendees who received HIV test result</b>   | 89% (74–100%) 10         | 81% (67–100%) 6          | 99% (85–100%) 3          | 87% (67–100%) 19         | 0.680              |
| <b>Percentage of HIV positive ANC attendees who received HIV test result</b>   | 93% (75–100%) 8          | 92% (60–100%) 6          | 96% (92–100%) 2          | 94% (60–100%) 16         | 0.957              |
| <b>Percentage of HIV positive ANC attendees given ARV prophylaxis at ANC</b>   | 53% (33–99%) 14          | 40% (22–89%) 5           | 60% (44–97%) 6           | 55% (22–99%) 25          | 0.784              |
| <b>Percentage of HIV positive ANC attendees given ARV prophylaxis at LW (on women who delivered at LW)</b>                             | 70% (19–100%) 11         | 70% (14–91%) 6           | 76% (43–95%) 5           | 74% (14–100%) 22         | 0.767              |
| <b>Percentage of HIV positive ANC attendees known to have taken ARV prophylaxis at delivery (self-reported and observed by nurses)</b> | 38% (19–75%) 12          | 60% (14–69%) 5           | 72% (43–85%) 5           | 52% (14–85%) 22          | 0.099              |

Abbreviations: ANC, antenatal care; ARV, antiretroviral; LW, labor ward; PMTCT, prevention of mother to child transmission.

<sup>a</sup>RankSumTrend test  $P=0.001$ .

<sup>b</sup>RankSumTrend test  $P=0.136$ .

doi:10.1371/journal.pone.0056550.t002

**PMTCT cascades.** The first cascade captures all the steps of the PMTCT program; from the pre-test counseling in antenatal care to the infant prophylaxis (Figure 2). It is based on the data from four studies reporting the uptake of each of the PMTCT interventions [46,47,58,61]. All studies were conducted in low-income sub-Saharan African countries and employed HIV rapid test and single dose nevirapine as ARV prophylaxis for both women and infants. Although most of the women attending antenatal care received pre-test counseling, only 70% of them accepted HIV testing and only 65% of those women received their test result.

About 14% of women attending the antenatal care received an HIV positive result. We estimated that an additional 4% of antenatal care attendees were HIV positive and unaware of their HIV status because they either were not counseled, were not tested, or did not receive test results. This translates to 22% of total HIV positive women attending the antenatal care who were not notified about their HIV status.

Only half of all HIV positive women attending the antenatal care were provided with ARV prophylaxis in antenatal care. Seventeen per cent of all HIV positive women attending the antenatal care were observed or self-reported to have taken the provided ARV prophylaxis at delivery. Similarly, only 17% of the infants born to all HIV positive women that attended antenatal care received ARV prophylaxis.

The second cascade presents the drop-outs of integrated PMTCT with labor ward (Figure 3) based on the results of three studies providing outcomes for PMTCT interventions provided in labor ward [52,75,78]. Ninety eight per cent of eligible women were counseled in labor ward and 89% of them were tested for HIV. Eighty nine per cent of all HIV positive women attending labor ward were diagnosed as infected. We estimated that an additional 11% of all HIV positive women attending labor ward were not identified as HIV-positive. Seventy eight per cent of all HIV positive women attending labor ward received ARV

**Table 3.** Uptake of integrated PMTCT programs in which women were enrolled at a labor ward.

| World Bank income group   | Low income               | Lower middle income      | Upper middle income      | All                      | P     |
|---|--------------------------|--------------------------|--------------------------|--------------------------|-------|
|   | Median (range) n studies | Median (range) n studies | Median (range) n studies | Median (range) n studies |       |
| <b>Percentage of women delivering at LW who received information on PMTCT</b>             | 69% (53–84%) 2           | 68% (59–100%) 3          | 100% (77–100%) 3         | 80% (53–100%) 8          | 0.306 |
| <b>Percentage of women delivering at LW who were HIV tested</b>                           | 59% (45–72%) 2           | 68% (44–98%) 3           | 89% (51–95%) 3           | 70% (44–98%) 8           | 0.505 |
| <b>Percentage of HIV positive women delivering at LW given ARV prophylaxis</b>            | 100% (N/A) 1             | 100% (100–100%) 2        | 77% (48–84%) 3           | 92% (48–100%) 6          | 0.351 |
| <b>Percentage of infants of HIV positive women delivering at LW given ARV prophylaxis</b> | 94% (89–100%) 2          | 88% (75–100%) 2          | 96% (85–98%) 3           | 96% (75–100%) 7          | 0.558 |

Abbreviations: ARV, antiretroviral; LW, labor ward; PMTCT, prevention of mother to child transmission of HIV.

doi:10.1371/journal.pone.0056550.t003

**Table 4.** Uptake of PMTCT interventions by infants born to HIV positive women.

| World Bank income group  | Low income               | Lower middle income      | Upper middle income      | All                      | P     |
|--|--------------------------|--------------------------|--------------------------|--------------------------|-------|
|  | Median (range) n studies | Median (range) n studies | Median (range) n studies | Median (range) n studies |       |
| Percentage of infants of HIV positive women given ARV prophylaxis    | 90% (24–100%) 12         | 100% (75–100%) 7         | 98% (85–100%) 7          | 97% (24–100%) 26         | 0.327 |
| Percentage of infants of HIV positive women HIV tested at least once | 67% (54–79%) 2           | 74% (44–100%) 4          | 82% (50–100%) 7          | 79% (44–100%) 13         | 0.548 |

Abbreviations: ARV, antiretroviral.  
doi:10.1371/journal.pone.0056550.t004

prophylaxis as well as 78% of the infants. The prevalence of HIV among the HIV tested women in the included studies was 2.8%.

**Secondary outcomes.** Percentage of HIV positive infants born to women living with HIV. Thirteen studies reported the uptake of infant HIV testing. A median of 11% (range 3–18%) of infants were found to be HIV positive [41,47,51,56,57,64,66,68,69,71,75,78,79].

**Cost analysis.** Three studies provided data on the costs of interventions [48,58,60].

A 12-month program in Zambia was estimated to cost US\$ 221 170. This included start-up costs and recurring costs such as staff salaries and HIV test kits, but excluded expatriate salaries and travel expenses. Subtracting the start-up costs from the overall expenditure, the costs were US\$ 9.34 per woman counseled, US\$ 12.96 per woman tested and US\$ 55.12 for identifying one seropositive woman. This program was funded by the Elizabeth Glaser Pediatric AIDS Foundation [48].


In a South African program the estimated costs per woman enrolled in a postpartum VCT program were US\$ 23; these costs

included testing women and administering nevirapine to infants whose women were positive [60].

The costs of preventing one HIV child infection was estimated in two studies to range from US\$ 848 in a Zambian study (where the initial costs of salaries, training, medical materials, equipment were excluded) [48], to US\$ 4444 in a Malawian study (where all the initial costs were included) [58].


**Impact of integration on human resources.** A number of studies reported that the integration of programs led to increased staff workload [51,52,59,74] and that additional personnel was employed [44,46,47,51,52,57,58,60,78]. New personnel hired were mostly counselors [44,46,58,60,78]. In some programs traditional birth attendants, lay counselors or peer-counselors were additionally employed [46,51,60–65].

One study reported that nurses received compensation because of extra work [63] and in a Zambian study the nurses were allowed to schedule counseling on their off-days for extra pay [48]. Heavy workload on personnel without extra pay was identified as potentially having a negative impact on the success of the program in the long-term [49].



**Figure 2.** Cascade of integrated perinatal PMTCT program in antenatal care. Blue bars indicate proportion of women participating in PMTCT program while red bars show the estimated proportion of undiagnosed HIV positive women and diagnosed HIV positive women lost to follow-up at each step of the PMTCT program.

doi:10.1371/journal.pone.0056550.g002



**Figure 3. Cascade of integrated PMTCT program at labor ward.** Blue bars indicate the proportion of women participating in PMTCT program at labor ward. Red bars show the estimated proportion of eligible HIV positive women at labor ward, not tested (column 1), not receiving ARV prophylaxis (column 2) and proportion of infants born to HIV positive women not receiving ARV prophylaxis (column 3). doi:10.1371/journal.pone.0056550.g003

**Inequalities in access.** Three studies identified lack of means as a key barrier to participation in PMTCT program [54,59,76]. In a study from Vietnam, there was a low uptake of HIV testing due to service charges. In the same study women were counseled to use infant formula which was provided for free only during the hospital stay but was unaffordable after discharge for most women [76]. In two studies, women opted for a home delivery since they were unable to pay for the maternity services [54,59].

In some studies women were lost-to follow-up due to lack of transportation [54,58,67]. In a Ukrainian study authors identified intravenous drug users as a hard to reach group not attending antenatal care but reporting to hospital in advanced labor [81].

**Confidentiality.** Some studies reported that the confidentiality of counseling was not always achieved due to partially opened doors, interruptions during counseling and lack of space for counseling [50,59,60]. Several studies presented activities undertaken to ensure confidentiality of counseling, e.g. additional space was either built in or designated for counseling [46,47,58,62,63], and patient confidentiality was emphasized during staff training [47,62,64,65,78].

**Barriers to implementation, access and sustainability.** Several studies identified lack of human, material, and financial resources (with stock-outs of HIV test kits, ARV prophylaxis and ART) as a key barrier to implementation of integrated care in low- and middle-income countries [50,61–64,67,74,76].

Social norms and stigma have been described in many studies as a cause of lower uptake of PMTCT interventions, HIV testing refusal [48,59,61,62,67], and for preference of breastfeeding even when formula was provided for free [44,74]. In one study families left their communities after women were identified as HIV positive [64]. In a Nigerian program, HIV positive women who were provided elective caesarean section preferred a vaginal delivery because of cultural aversion to caesarean section [45]. In a study in rural Cameroon, the health worker counseled women to breastfeed their infants instead of using the available formula milk because replacement feeding was considered culturally unacceptable [65].

Complexity of monitoring tools deterred health workers from completing them or following up women [47,55,74,78]. One study reported that health workers were reluctant to give ARV prophylaxis to women in antenatal care as they believed women would not take the medication provided [50].

Late admission to the labor ward sometimes prevented staff from testing women for HIV, receiving the result before delivery and providing them with ARV prophylaxis [70,75,84].

Two studies reported that some HIV positive women abandoned their children at hospitals [73,76]. These infants did not receive ARV prophylaxis or HIV testing, as there were no follow-up services available [76].

The most commonly reported barrier to sustainability was the lack of financial support. Funding provided by the government or/and external donors has been reported as crucial for the success and sustainability of programs [61,65,74,78]. Authors reporting on the PMTCT program from rural Malawi argued that it should be decentralized in the future to improve access. However, they also felt that in that case the provision of free formula would no longer be affordable [58].

Impact of integration on the use of healthcare services integrated with PMTCT interventions was reported in only one study where it did not influence the coverage or flow of women attending antenatal care given as counseling was provided by counselors in separate rooms [46].

The remaining secondary outcomes are presented in Text S8. We presented community involvement strategies employed in the included studies. We also reported data on provision of ART and co-trimoxazole to HIV positive mothers and HIV positive infants after delivery.

## Discussion

This is the first systematic review on the uptake of integrated PMTCT programs in low- and middle-income countries. The existing evidence provides data on PMTCT programs implemented between 1997 and 2006. The overall uptake of PMTCT programs was low. The MTCT rate of HIV in included studies was 11% (range 3–18%). It highlighted many challenges of following through all the steps of the perinatal PMTCT cascade.

Although the uptake of counseling and testing in antenatal care was high, presumably many HIV positive women did not receive ARV prophylaxis in antenatal care and did not deliver at a labor ward. The PMTCT cascade based on the four studies from low-income sub-Saharan African countries with data on the entire perinatal PMTCT program showed a marked loss to follow-up between steps of the program. Only half of HIV positive women received ARV prophylaxis in antenatal care and 17% were known to have taken ARV prophylaxis at delivery (either self-reported or observed at labor ward). We estimated that 22% of all HIV positive women attending antenatal care and 11% of all HIV positive women attending labor ward were not tested or notified about their HIV status. Although the uptake of PMTCT interventions delivered at labor ward was high, it did not reach the 80% target set by UNGASS for HIV testing [16].

In a study performed in four African countries cord blood specimen analysis was used to assess uptake of ARV prophylaxis instead of process indicators. The unadjusted maternal nevirapine coverage was 58% (95% CI, 56–59%) [85]. These findings are strikingly consistent with the findings of this review where 55% (range 22–99%) of HIV positive women received ARV prophylaxis in antenatal care and 52% (range 14–85%) of HIV positive women were known to have taken ARV prophylaxis. However, more recent studies generally report lower ingestion of ARV prophylaxis among HIV positive women within antenatal care which could be due to the more complicated regimens of ARV prophylaxis used lately.

The uptake of ARV prophylaxis at labor ward in women entering PMTCT program at labor ward was 92% compared to 74% of those entering in antenatal care. We assume that this difference is due to late admission of women to the labor ward. Identified HIV positive women arriving at the labor wards were sometimes not provided with ARV prophylaxis because of imminent delivery and lack of time. Further, in the studies reviewed women of unknown HIV status arriving to the labor ward in advanced labor were not tested and diagnosed. Consequently, they were not considered eligible for ARV prophylaxis and are not included in the denominator (HIV positive women delivering at labor ward) misleadingly resulting in higher proportion of women receiving ARV prophylaxis. Furthermore, the higher proportion of participants receiving ARV prophylaxis at labor ward compared to the antenatal care could also be explained by the complexity of the provided ARV prophylaxis. At labor ward, the ARV prophylaxis consisted mostly of single dose nevirapine while in antenatal care women also received more complex regimens. We also observed an excellent correlation of women and infants receiving ARVs at institutional delivery.

This review also showed that not all interventions which should intuitively lead to better outcomes necessarily do so. The opt-out approach increased the proportion of women tested. However, it is unclear if it improves uptake of other PMTCT interventions such as counseling or ARV prophylaxis. Increased awareness of HIV positive serostatus might not lead to more women participating in PMTCT program due to other barriers such as health system failures or fear of stigma. Several studies confirmed higher uptake of HIV testing when opt-out approach was implemented [86–89]. Studies from Botswana and Ethiopia reported that opt-out testing lead to better uptake of only testing [86,88]. A Zimbabwean study reported also an increase in uptake of ARV prophylaxis [89]. Similarly, the implementation of rapid test increased the proportion of women receiving their test result but the difference was not significant when only HIV positive women were considered. Several studies on the effect of rapid test on the

PMTCT intervention uptake reported contrasting findings. Rapid test contributed to an increase in the proportion of women who received post-test counseling in two studies [89,90]. In a Kenyan study significantly fewer HIV positive women were tested with rapid test and accepted referral for other PMTCT interventions compared to those receiving conventional tests [91].

Next, the use of virological test for infants, which means a shorter length of follow up, did not result in a higher proportion of infants tested.

In many countries significant proportion of women delivers at home. One strategy for reaching these women and their infants is the involvement of traditional birth attendants (TBAs). This approach seems to be effective according to two studies from Cameroon [64,65]. A further Zimbabwean study examining the views of TBAs regarding PMTCT programs, reported that TBAs were willing to participate in most of the PMTCT interventions [92]. Furthermore, TBAs could potentially act as a link to long-term HIV care and treatment services for HIV positive women and children in need of lifelong HAART. This systematic review has a number of strengths. We undertook a comprehensive and extensive search of multiple electronic databases of published and grey literature to identify relevant peer-reviewed studies since the introduction of the PMTCT. We neither used any methodological filters, nor specific search terms for integrated care. We followed methodology principles established by the Cochrane Collaboration and did not apply language restrictions to the search strategy. A detailed and comprehensive data extraction of the selected studies has provided us with a broad range of information and deep insight into the issues surrounding the implementation of integrated PMTCT programs.

Despite our thorough search strategy, we only found studies presenting programs implemented before 2007. It could be argued that the data from our review does not reflect the current, potentially better PMTCT programs which have, in the last few years, received substantial financial investments and could have improved. However, the aforementioned study on uptake in four African countries during 2007 and 2008 showed very similar uptake of PMTCT interventions to the one in our review. In addition, a study presenting national data on PMTCT services in Ethiopia from 2006 to 2010, showed that uptake was low. Although there was significant improvement in HIV counseling and testing uptake during this period, only 53% of known HIV-positive mothers and 38% of known HIV-exposed infants attending PMTCT programs have received ARV prophylaxis in 2009.[88] Furthermore, recent WHO PMTCT guidelines recommend more effective and more complicated regimens. Given the low uptake of simpler PMTCT regimens in the included studies, it is very important to assess the uptake of more recent PMTCT programs following new guidelines. It is of concern that we could not find studies with this information. The potential reason for lack of this information could be that the studies that we found were mostly published with the intention to present the feasibility of the first PMTCT programs. In addition, studies on uptake of PMTCT interventions are mostly based on routine program data and as such could potentially be considered as non-publishable in peer-reviewed journals, especially now that the feasibility of PMTCT programs has been established. However, the low uptake of these programs warrants more recent data which would show the current status of PMTCT services.

The included studies were highly heterogeneous in terms of time of implementation, content and context of implementation (i.e. HIV prevalence, type of HIV epidemic, dominant mode of HIV transmission or countries' income, training provided to the staff). However, we have used appropriate statistical methods that



allowed pooling of the studies. As sample size was limited in each study, we summarized results based on reported frequencies. This yielded higher sample size and higher external validity on cost of biases introduced by the heterogeneity of the studies and their different sample sizes.

We also found the policy context to be quite variable across the included studies. The timing of ARV prophylaxis administration in antenatal care was different and might have also had an impact on the uptake.

Included studies had several limitations which should be considered when interpreting these findings. The characteristics of participants were poorly reported in most of the studies. Additionally, there was a paucity of information about the setting of integrated PMTCT care, the nature of intervention and the content of the training provided to the staff. Although this systematic review was focused on the integration of service delivery, we noticed the general lack of data on integration of other aspects of the health system (e.g. health information systems, leadership, financing etc.). The studies were mostly based on single health facilities and given high levels of short-term migration of women at the time of delivery, might have failed to capture the potential uptake of ARV prophylaxis at other facilities. Although we aimed to capture the proportion of women receiving the full ARV prophylaxis regimen in the antenatal care, in two included studies we only found data on the proportion of women who started it. Most of the studies reported who funded the PMTCT programs, but there was no information on the proportion of financing from domestic versus international sources, per person or total annual financing for PMTCT as a proportion of the HIV or health budget. Many studies did not provide clear, quantitative data on the proportion of women counseled on infant feeding, costs, impact on maternal and child healthcare services attendance and stigma. The information on follow-up of HIV positive women and infants after the delivery was scarce. We also wanted to present other aspects of quality of care in the integrated programs but only found information on confidentiality of counseling. However, these studies were primarily focused on perinatal programs, presented programs implemented before the new WHO guidelines on follow-up. Our ability to detect statistically significant difference in subgroup analyses was limited by the low number of studies reporting on coverage of individual interventions.

The findings of our review provide most timely information on weaknesses in and the uptake of PMTCT cascade at the time when PMTCT is receiving a reinvigorated commitment and scaling-up is the highest priority of all main players in global health from governments to global agencies and financing institutions. The findings are important and inform the global estimates of the impact of PMTCT interventions as we provide the most up to date status of how initial coverage levels translate to effective prophylaxis for prevention of MTCT of HIV. Models used to estimate coverage and impact of PMTCT interventions need to factor adequately for the 'substantial' attrition rates to produce a more realistic estimate of coverage impact.

If the ambition of HIV-free and AIDS-free generation is to be achieved by 2015 [93], implementation strategies for PMTCT programs need to receive much greater attention for each step of the cascade.

Future research should in particular focus on the strategies to improve access to maternal and child healthcare services (perhaps through more systematic use of mobile phones) and to provide PMTCT interventions to HIV positive women delivering at home. Given that the main challenge is reaching the women who are not attending antenatal care or delivering at a labor ward, it is

necessary to evaluate outreach options and the use of healthcare services other than maternal and child healthcare programs as entry points to the PMTCT programs.

## Supporting Information

### **Figure S1 Year of initiation of the described PMTCT programs.**

(DOCX)

### **Table S1 Framework for the integration of PMTCT program with maternal and child healthcare Services.**

(DOCX)

### **Table S2 Data extraction headings.**

(DOCX)

### **Table S3 Search results by source.**

(DOCX)

### **Table S4 Excluded studies and reasons of exclusion.**

(DOCX)

### **Table S5 HIV prevalence in the included studies.**

(DOCX)

### **Table S6 Number of studies providing various types of ARV prophylaxis.**

(DOCX)

### **Text S1 The World Health Organization definition of PMTCT program.**

(DOCX)

### **Text S2 List of primary and secondary outcomes.**

(DOCX)

### **Text S3 Exclusion criteria.**

(DOCX)

### **Text S4 Search strategy.**

(DOCX)

### **Text S5 Description of denominators.**

(DOCX)

### **Text S6 Description of setting, participants and staff from the included studies.**

(DOCX)

### **Text S7 Description of PMTCT interventions.**

(DOCX)

### **Text S8 Data about subgroup analysis, community involvement and maternal and infant follow-up.**

(DOCX)

## Acknowledgments

We are very grateful to Tapio Paljarvi for commenting on the protocol, running the searches and contributing to the study selection process. We would also like to express our gratitude to Joy Oliver from the Cochrane HIV/AIDS group and Rosemary J. Brownhill and Emma L. Shaw from Medicine Central Library, Imperial College London for helping us develop the search strategy.

## Author Contributions

Contributed to the writing of the paper: VW PT AM IR JC. Conceived and designed the experiments: JC RA. Performed the experiments: LTC SB HE MVV UP. Analyzed the data: LTC SB HE MVV UP. Wrote the paper: LTC SB HE MVV UP.



## References

- UNAIDS (2010) Global report: UNAIDS report on the global AIDS epidemic.
- Mazia G, Narayanan I, Warren C, Mahdi M, Chibuye P, et al. (2009) Integrating quality postnatal care into PMTCT in Swaziland. *Glob Public Health* 4: 253–270.
- Nkonki LL, Doherty TM, Hill Z, Chopra M, Schaay N, et al. (2007) Missed opportunities for participation in prevention of mother to child transmission programmes: simplicity of nevirapine does not necessarily lead to optimal uptake, a qualitative study. *AIDS Res Ther* 4: 27.
- WHO/UNAIDS/UNICEF (2010) Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Geneva: WHO.
- WHO (2010) PMTCT strategic vision 2010–2015: preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals. Geneva: WHO.
- Ginsburg AS, Hoblitzelle CW, Sripipatana TL, Wilfert CM (2007) Provision of care following prevention of mother-to-child HIV transmission services in resource-limited settings. *AIDS* 21: 2529–2532.
- WHO (2006) Technical Consultation on the Integration of HIV Interventions into Maternal, Newborn and Child Health Services. Geneva: WHO.
- WHO (2005) Glion consultation on strengthening the linkages between reproductive health and HIV/AIDS: family planning and HIV/AIDS in women and children. Geneva: WHO.
- IPPF UNFPA, WHO UNAIDS, GNP+, et al. (2009) Rapid Assessment Tool for Sexual & Reproductive Health and HIV Linkages: A Generic Guide.
- Israeli E, Kroeger M (2003) Integrating Prevention of Mother-to-Child HIV Transmission into Existing Maternal, Child, and Reproductive Health Programs. Technical Guidance Series.
- WHO (2010) World health statistics 2010. Geneva, Switzerland: WHO.
- WHO/UNAIDS (2007) Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva: WHO.
- WHO (2010) Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Geneva: WHO.
- Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer GV, et al. (1995) Seroreversion in human immunodeficiency virus-exposed but uninfected infants. *Pediatr Infect Dis J* 14: 382–387.
- Rakusan TA, Parrott RH, Sever JL (1991) Limitations in the laboratory diagnosis of vertically acquired HIV infection. *J Acquir Immune Defic Syndr* 4: 116–121.
- United Nations General Assembly Special Session (2001) Declaration of Commitment on HIV/AIDS. New York.
- Inter-Agency Task Team (2007) Guidance on global scale-up of the prevention of mother-to-child transmission of HIV: Towards universal access for women, infants and young children and eliminating HIV and AIDS among children. Geneva: WHO/UNICEF.
- Hogan MC, Foreman KJ, Naghavi M, Ahn SY, Wang M, et al. (2010) Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5. *Lancet* 375: 1609–1623.
- Rajaratnam JK, Marcus JR, Flaxman AD, Wang H, Levin-Rector A, et al. (2010) Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970–2010: a systematic analysis of progress towards Millennium Development Goal 4. *Lancet* 375: 1988–2008.
- United Nations Secretary-General (2010) Global Strategy for Women's and Children's health. The Partnership for Maternal, Newborn and Child Health.
- G8 (2010) G8 Muskoka Declaration Recovery and New Beginnings. Muskoka, Canada.
- The Global Fund (2010) The Global Fund Information Note: PMTCT Geneva: The Global Fund to fight AIDS, Tuberculosis and Malaria.
- Church K, Mayhew SH (2009) Integration of STI and HIV prevention, care, and treatment into family planning services: a review of the literature. *Stud Fam Plann* 40: 171–186.
- Dehne KL, Snow R, O'Reilly KR (2000) Integration of prevention and care of sexually transmitted infections with family planning services: what is the evidence for public health benefits? *Bull World Health Organ* 78: 628–639.
- Druce N, Dickinson D, Attawell K, Campbell White A, Standing H (2006) Strengthening linkages for sexual and reproductive health, HIV and AIDS: progress, barriers and opportunities for scaling up.
- Moore M (2003) A Behavior Change Perspective on Integrating PMTCT and Safe Motherhood Programs: A Discussion Paper. Washington: The CHANGE Project AED/The Manoff Group.
- Paintsil E, Andiman WA (2009) Update on successes and challenges regarding mother-to-child transmission of HIV. *Curr Opin Pediatr* 21: 94–101.
- Mofenson LM (1999) Can perinatal HIV infection be eliminated in the United States? *Jama* 282: 577–579.
- Atun R, Lazarus JV, Van Damme W, Coker R (2010) Interactions between critical health system functions and HIV/AIDS, tuberculosis and malaria programmes. *Health Policy Plan* 25 Suppl 1: i1–3.
- Criel B, De Brouwere V, Dugas S (1997) Integration of Vertical Programmes in Multi-Function Health Services; Van Lerberghe WK, G. . De Brouwere, V., editor. Antwerp, Belgium: ITG Press.
- Mills A (1983) Vertical vs horizontal health programmes in Africa: idealism, pragmatism, resources and efficiency. *Soc Sci Med* 17: 1971–1981.
- Shigayeva A, Atun R, McKee M, Coker R (2010) Health systems, communicable diseases and integration. *Health Policy Plan* 25 Suppl 1: i4–20.
- WHO (2008) Sexual and reproductive health and HIV linkages: evidence review and recommendations. Geneva: WHO.
- The World Bank (2010) The World Bank Country Income Groups. Washington: World Bank.
- Wilcoxon F (1945) Individual comparisons by ranking methods. *Biometrics* 1: 80–83.
- Cuzick J (1985) A Wilcoxon-type test for trend. *Stat Med* 4: 87–90.
- Doull M, O'Connor A, Jacobsen MJ, Robinson V, Cook L, et al. (2006) Investigating the decision-making needs of HIV-positive women in Africa using the Ottawa Decision-Support Framework: Knowledge gaps and opportunities for intervention. *Patient Educ Couns* 63: 279–291.
- Tugwell P, de Savigny D, Hawker G, Robinson V (2006) Applying clinical epidemiological methods to health equity: the equity effectiveness loop. *BMJ* 332: 358–361.
- Kirere MM, Lepage P (2007) Feasibility of HIV prophylaxis with nevirapine in a northeastern rural area of the Democratic Republic of the Congo. *Cahiers Sante* 17: 97–101.
- Perez F, Orne-Gliemann J, Mukotekwa T, Miller A, Glenshaw M, et al. (2004) Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. *BMJ* 329: 1147–1150.
- Garcia R, Prieto F, Arenas C, Rincon J, Caicedo S, et al. (2005) [Reduction of HIV mother-to-child transmission in Colombia, two years of experience, 2003–2005]. *Biomedica* 25: 547–564.
- Abdullah MF, Young T, Bitalo L, Coetzee N, Myers JE (2001) Public health lessons from a pilot programme to reduce mother-to-child transmission of HIV-1 in Khayelitsha. *S Afr Med J* 91: 579–583.
- Ekouevi DK, Leroy V, Viho I, Bequet L, Horo A, et al. (2004) Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, Cote d'Ivoire. *AIDS* 18: 697–700.
- Msellati P, Hingst G, Kaba F, Viho I, Wellfens-Ekra C, et al. (2001) Operational issues in preventing mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire, 1998–99. *Bull World Health Organ* 79: 641–647.
- Onah HE, Ibeziako N, Nkwo PO, Obi SN, Nwankwo TO (2008) Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital. *J Obstet Gynaecol* 28: 276–279.
- Perez F, Mukotekwa T, Miller A, Orne-Gliemann J, Glenshaw M, et al. (2004) Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. *Trop Med Int Health* 9: 774–783.
- Rutta E, Gongo R, Mwansasu A, Mutasingwa D, Rwegasira V, et al. (2008) Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania. *Glob Public Health* 3: 62–76.
- Stringer EM, Sinkala M, Stringer JS, Mzyece E, Makuka I, et al. (2003) Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. *AIDS* 17: 1377–1382.
- Temmerman M, Quaghebeur A, Mwanyumba F, Mandaliya K (2003) Mother-to-child HIV transmission in resource poor settings: how to improve coverage? *AIDS* 17: 1239–1242.
- Behets F, Mutombo GM, Edmonds A, Dulli L, Belting MT, et al. (2009) Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery. *AIDS Care* 21: 583–590.
- Doherty TM, McCoy D, Donohue S (2005) Health system constraints to optimal coverage of the prevention of mother-to-child HIV transmission programme in South Africa: lessons from the implementation of the national pilot programme. *Afr Health Sci* 5: 213–218.
- Homsy J, Kalamya JN, Obonyo J, Ojwang J, Mugumya R, et al. (2006) Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital. *J Acquir Immune Defic Syndr* 42: 149–154.
- Karcher H, Kunz A, Poggensee G, Mbezi P, Mugenyi K, et al. (2006) Outcome of Different Nevirapine Administration Strategies in Preventing Mother-to-Child Transmission (PMTCT) Programs in Tanzania and Uganda. *J Int AIDS Soc* 8: 12.
- Kasenga F, Hurtig AK, Emmelin M (2007) Home deliveries: implications for adherence to nevirapine in a PMTCT programme in rural Malawi. *AIDS Care* 19: 646–652.
- Kirere MM, Sondag-Thull D, Lepage P (2008) Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002–2004. *J Med Virol* 80: 772–776.
- Kouam L, Nsangou I, Mbanya D, Nkam M, Kongnyuy EJ, et al. (2006) Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon). *Zentralbl Gynaekol* 128: 82–86.
- Magoni M, Okong P, Bassani L, Kituka NP, Onyango S, et al. (2007) Implementation of a programme for the prevention of mother-to-child transmission of HIV in a Ugandan hospital over five years: challenges, improvements and lessons learned. *Int J STD AIDS* 18: 109–113.

58. Manzi M, Zachariah R, Teck R, Buhendwa L, Kazima J, et al. (2005) High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. *Trop Med Int Health* 10: 1242–1250.
59. Moth IA, Ayayo ABCO, Kaseje DO (2005) Assessment of utilisation of PMTCT services at Nyanza Provincial Hospital, Kenya. *SAHARA J* 2: 244–250.
60. Rose P, Violaro A, Bolton C, Gray GE (2005) Feasibility and acceptability of postpartum voluntary counselling and testing (PPVCT) in a large tertiary hospital in the South African setting. *South Afr J HIV Med* 8: 8–10.
61. Shetty AK, Marangwanda C, Stranix-Chibanda L, Chandisarewa W, Chirapa E, et al. (2008) The feasibility of preventing mother-to-child transmission of HIV using peer counselors in Zimbabwe. *AIDS Res Ther* 5: 17.
62. Shetty AK, Mhazo M, Moyo S, von LA, Mateta P, et al. (2005) The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe. *Int J STD AIDS* 16: 755–759.
63. Torpey K, Kabaso M, Kasonde P, Dirks R, Bweupe M, et al. (2010) Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. *BMC Health Serv Res* 10: 29.
64. Wanyu B, Diom E, Mitchell P, Tih PM, Meyer DJ (2007) Birth attendants trained in "Prevention of Mother-To-Child HIV Transmission" provide care in rural Cameroon, Africa. *J Midwifery Womens Health* 52: 334–341.
65. Welty TK, Bulterys M, Welty ER, Tih PM, Ndikintum G, et al. (2005) Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon. *J Acquir Immune Defic Syndr* 40: 486–493.
66. Geddes R, Knight S, Reid S, Giddy J, Esterhuizen T, et al. (2008) Prevention of mother-to-child transmission of HIV programme: low vertical transmission in KwaZulu-Natal, South Africa. *S Afr Med J* 98: 458–462.
67. Deschamps MM, Noel F, Bonhomme J, Devieux JG, Saint-Jean G, et al. (2009) Prevention of mother-to-child transmission of HIV in Haiti. *Rev Panam Salud Publica* 25: 24–30.
68. Miranda AE, Soares RA, Prado BC, Monteiro RB, Figueiredo NC (2005) Mother to child transmission of HIV in Vitoria, Brazil: factors associated with lack of HIV prevention. *AIDS Care* 17: 721–728.
69. Saraceni V, Rapparini C, Fonseca AF AF, Lima KR, Israel G, et al. Prevention of mother to child HIV transmission - a public health matter in Rio de Janeiro City; 2000; Durban, South Africa.
70. Schumacher S, Norin J, Bolu O, Dubois A, Wolford J, et al. (2009) HIV testing and counselling for prevention of mother-to-child transmission at labour and delivery in Guyana. *West Indian Medical Journal* 58: 112–113.
71. Viani RM, Ruiz-Calderon J, Lopez G, Chacon-Cruz E, Spector SA (2010) Mother-to-child HIV transmission in a cohort of pregnant women diagnosed by rapid HIV testing at Tijuana General Hospital, Baja California, Mexico. *J Int Assoc Physicians AIDS Care (ChicIll)* 9: 82–86.
72. Bharucha KE, Sastry J, Shrotri A, Sutar S, Joshi A, et al. (2005) Feasibility of voluntary counselling and testing services for HIV among pregnant women presenting in labour in Pune, India. *Int J STD AIDS* 16: 553–555.
73. Hillis SD, Rakhmanova A, Vinogradova E, Voronin E, Yakovlev A (2007) Rapid HIV testing, pregnancy, antiretroviral prophylaxis and infant abandonment in St Petersburg. *Int J STD AIDS* 18: 120–122.
74. Kanshana S, Thewanda D, Teeraratkul A, Limpakarnjanarat K, Amornwichee P, et al. (2000) Implementing short-course zidovudine to reduce mother-infant HIV transmission in a large pilot program in Thailand. *AIDS* 14: 1617–1623.
75. Kissin DM, Akatova N, Rakhmanova AG, Vinogradova EN, Voronin EE, et al. (2008) Rapid HIV testing and prevention of perinatal HIV transmission in high-risk maternity hospitals in St. Petersburg, Russia. *Am J Obstet Gynecol* 198: 183–187.
76. Le CT, Vu TT, Luu MC, Do TN, Dinh TH, et al. (2008) Preventing mother-to-child transmission of HIV in Vietnam: an assessment of progress and future directions. *J Trop Pediatr* 54: 225–232.
77. Nagdeo N, Thombare VR (2007) Prevention of parent-to-child transmission of HIV: an experience in rural population. *Indian J Med Microbiol* 25: 425.
78. Pai NP, Barick R, Tulsy JP, Shivkumar PV, Cohan D, et al. (2008) Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. *PLoS Med* 5: e92.
79. Parameshwari S, Jacob MS, Vijayakumari J, Shalini D, Sushi MK, et al. (2009) A Program on Prevention of Mother to Child Transmission of HIV at Government Hospital, Tiruchengode Taluk, Namakkal District. *Indian J Community Med* 34: 261–263.
80. Saman M, Kruiy LS, Glaziou P, Rekacewicz C, Leng C, et al. (2002) Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study. *AIDS* 16: 950–951.
81. Malyuta R, Newell ML, Ostergren M, Thorne C, Zhilka N (2006) Prevention of mother-to-child transmission of HIV infection: Ukraine experience to date. *Eur J Public Health* 16: 123–127.
82. Homsy J, Moore D, Barasa A, Were W, Likicho C, et al. (2010) Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. *J Acquir Immune Defic Syndr* 53: 28–35.
83. Back C, Rutenberg N (2010) Implementing programs for the prevention of mother-to-child HIV transmission in resource-constrained settings: Horizons studies, 1999–2007. *Public Health Rep* 125: 293–304.
84. Amornwichee P, Teeraratkul A, Simonds RJ, Naiwatanakul T, Chantharojwong N, et al. (2002) Preventing mother-to-child HIV transmission: the first year of Thailand's national program. *JAMA* 288: 245–248.
85. Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, et al. (2010) Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. *JAMA* 304: 293–302.
86. MMWR (2004) Introduction of routine HIV testing in prenatal care--Botswana, 2004. *MMWR Morb Mortal Wkly Rep* 53: 1083–1086.
87. Byamugisha R, Tylleskar T, Kagawa MN, Onyango S, Karamagi CA, et al. (2010) Dramatic and sustained increase in HIV-testing rates among antenatal attendees in Eastern Uganda after a policy change from voluntary counselling and testing to routine counselling and testing for HIV: a retrospective analysis of hospital records, 2002–2009. *BMC Health Serv Res* 10: 290.
88. Mirkuzie AH, Hinderaker SG, Morkve O (2010) Promising outcomes of a national programme for the prevention of Mother-to-Child HIV transmission in Addis Ababa: a retrospective study. *BMC Health Serv Res* 10: 267.
89. Chandisarewa W, Stranix-Chibanda L, Chirapa E, Miller A, Simoyi M, et al. (2007) Routine offer of antenatal HIV testing ("opt-out" approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe. *Bull World Health Organ* 85: 843–850.
90. Bolu OO, Allread V, Creek T, Stringer E, Forna F (2007) Approaches for scaling up human immunodeficiency virus testing and counseling in prevention of mother-to-child human immunodeficiency virus transmission settings in resource-limited countries. *Am J Obstet Gynecol* 197: S83–S89.
91. Malonza IM, Richardson BA, Kreiss JK, Bwayo JJ, Stewart GC (2003) The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial. *AIDS* 17: 113–118.
92. Perez F, Aung KD, Ngoro T, Engelsmann B, Dabis F (2008) Participation of traditional birth attendants in prevention of mother-to-child transmission of HIV services in two rural districts in Zimbabwe: a feasibility study. *BMC Public Health* 8.
93. UNICEF (2010) Children and AIDS: Fifth Stocktaking Report, 2010.
94. Perez F, Orne-Gliemann J, Mukotekwa T, Miller A, Glenshaw M (2004) Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. *BMJ British Medical Journal* 329: 1147–1150.